AI assistant
Sending…
Candel Therapeutics, Inc. — Director's Dealing 2021
Aug 3, 2021
33336_dirs_2021-08-02_d3ae3185-0604-47e0-9f6d-e3b4b2880308.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Candel Therapeutics, Inc. (CADL)
CIK: 0001841387
Period of Report: 2021-07-29
Reporting Person: Caffo Nathan (Chief Business Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-07-29 | Common Stock | P | 6000 | $8.00 | Acquired | 6000 | Direct |
More from Candel Therapeutics, Inc.
Regulatory Filings
2026
May 15
Interim / Quarterly Report
2026
May 14
Report Publication Announcement
2026
May 14
Director's Dealing
2026
Feb 26
Capital/Financing Update
2026
Feb 23
Regulatory Filings
2026
Feb 19
Director's Dealing
2026
Jan 28
Director's Dealing
2026
Jan 28
Director's Dealing
2026
Jan 28
Director's Dealing
2026
Jan 28